Loading stock data…
TLPH
$0.92+0.01 (+1.06%)
Market ClosedLast close May 1
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Talphera, Inc. in the Healthcare sector is trading at $0.92. The stock is currently 41% below its 52-week high of $1.57, remaining 0.9% above its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why TLPH maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.92
Potential Upside
5%
Whystock Fair Value$0.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$39.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-83.89%
Volume
Today's trading volume
168,250
Recent News
Talphera: Q4 Earnings Snapshot
SAN MATEO, Calif. AP) — Talphera, Inc. TLPH) on Monday reported a loss of $3.8 million in its fourth quarter.
This Talphera Insider Increased Their Holding By 138% Last Year
Looking at Talphera, Inc.'s ( NASDAQ:TLPH ) insider transactions over the last year, we can see that insiders were net...
Talphera (TLPH) Q3 2025 Earnings Call Transcript
Beyond the NIAID opportunity, the recent investments were catalyzed by our efforts at the end of last year to restructure the nephro clinical study, which included changing the target profile for clinical sites and investigators and approaching the FDA with various study protocol changes, including the reduction of the study size from 166 to 70 patients with a goal of accelerating the completion of the study. The results of this restructuring were evident last quarter with the acceleration in the enrollment rate from our existing sites, which continued into the third quarter.
Talphera Inc (TLPH) Q3 2025 Earnings Call Highlights: Strategic Investments and Regulatory ...
Talphera Inc (TLPH) secures crucial financing and navigates regulatory pathways while facing delays in clinical study site activations.
Talphera: Q3 Earnings Snapshot
SAN MATEO, Calif. AP) — Talphera, Inc. TLPH) on Wednesday reported a loss of $4.4 million in its third quarter.